Blue Biofuels, Inc. filed its Form 10-Q for the quarter ended September 30, 2026, with the SEC on November 13, 2026, reporting continued operating losses and zero revenues across all reported periods.

Key Highlights

  • No revenues recorded: According to the filing, the company reported $0 in revenues for both the three and nine months ended September 30, 2026, and September 30, 2025.
  • Nine-month net loss of $2,799,864: The company disclosed a net loss of $2,799,864 for the nine months ended September 30, 2026, compared to a net loss of $1,587,132 in the same period of 2025.
  • Q3 net loss of $1,385,268: The filing reported a net loss of $1,385,268 for the three months ended September 30, 2026, versus a net loss of $422,547 in Q3 2025.
  • Accumulated deficit of $62,930,226: As of September 30, 2026, the registrant reported an accumulated deficit of $62,930,226, up from $60,130,362 at December 31, 2025.
  • Total stockholders' deficit of $(4,546,983): The balance sheet reflected a total stockholders' deficit of $(4,546,983) at September 30, 2026, compared to $(3,706,083) at December 31, 2025.
  • Cash declined to $6,473: Cash and cash equivalents fell to $6,473 as of September 30, 2026, from $65,200 at December 31, 2025.
  • Shares outstanding at 324,418,980: The filing stated 324,418,980 shares of common stock were issued and outstanding as of October 31, 2026.

Blue Biofuels Financial Results for the Nine Months Ended September 30, 2026

Blue Biofuels, Inc. (OTCQB:BIOF), a Nevada-incorporated smaller reporting company based in Palm Beach Gardens, Florida, disclosed in its quarterly filing that total operating expenses for the nine months ended September 30, 2026, reached $2,772,249, compared to $2,427,662 in the same period of 2025. The company attributed those costs primarily to general and administrative expenses of $1,227,185 and research and development expenses of $1,642,564 for the nine-month period. No revenues were recognized in either year.

For the three months ended September 30, 2026, operating expenses were $1,381,645, comprised of general and administrative costs of $555,192 and research and development costs of $826,453. The filing noted that the prior-year comparable quarter included grants income of $420,030, which the current quarter did not. Total other expenses for the nine months were $27,615, consisting entirely of interest expense to related parties, compared to other income of $840,530 in the prior-year nine-month period that included $865,000 in grants income.

The balance sheet showed total liabilities of $5,899,301 at September 30, 2026, against total assets of $1,352,318, resulting in a net liabilities position. Current liabilities included deferred wages and directors fees to related parties of $3,014,084 and convertible notes payable of $274,000 to non-related parties. During the nine months ended September 30, 2026, the company raised cash through private placements and issued shares for services and warrant exercises, as reflected in the stockholders' deficit statement. The filing also recorded stock-based compensation of $805,834 in the third quarter alone under the employee and director plan.

What Was Disclosed

Blue Biofuels filed its unaudited quarterly report covering the three and nine months ended September 30, 2026, disclosing zero revenues, a nine-month net loss of $2,799,864, cash of $6,473, and a total stockholders' deficit of $(4,546,983) at period end.